These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8725044)

  • 61. Is there a relationship between androgenic alopecia and benign prostatic hyperplasia?
    Dastgheib L; Shirazi M; Moezzi I; Dehghan S; Sadati MS
    Acta Med Iran; 2015; 53(1):30-2. PubMed ID: 25597602
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
    J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Serum PSA and transition zone index as predictors of acute urinary retention in benign prostate hyperplasia].
    Zhu S; Chen S; Li Q; Lin Z; Zheng S; Weng M
    Zhonghua Nan Ke Xue; 2004 Jan; 10(1):24-5. PubMed ID: 14979202
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Interactions between benign prostatic hyperplasia (BPH) and prostate cancer in large prostates: a retrospective data review.
    Al-Khalil S; Boothe D; Durdin T; Sunkara S; Watkins P; Yang S; Haynes A; de Riese W
    Int Urol Nephrol; 2016 Jan; 48(1):91-7. PubMed ID: 26590832
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Asymptomatic prostatic inflammation in men with clinical BPH and erectile dysfunction affects the positive predictive value of prostate-specific antigen.
    Agnihotri S; Mittal RD; Kapoor R; Mandhani A
    Urol Oncol; 2014 Oct; 32(7):946-51. PubMed ID: 24996777
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Relationships between American Urological Association symptom index, prostate volume, and disease-specific quality of life question in patients with benign prostatic hyperplasia.
    Liu CC; Wang CJ; Huang SP; Chou YH; Wu WJ; Huang CH
    Kaohsiung J Med Sci; 2004 Jun; 20(6):273-8. PubMed ID: 15253468
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma.
    Bretton PR; Evans WP; Borden JD; Castellanos RD
    Cancer; 1994 Dec; 74(11):2991-5. PubMed ID: 7525040
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH).
    Liu Q; Zhu Y; Liu J; Qi J; Kang J
    Int Urol Nephrol; 2017 Mar; 49(3):399-404. PubMed ID: 27987130
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Results of studies of prostate-specific antigen and prostate-specific antigen density in patients with prostatic hypertrophy and prostatic cancer].
    Romics I; Bodrogi I; Frang D
    Orv Hetil; 1995 Jul; 136(30):1599-602. PubMed ID: 7543669
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level.
    Punglia RS; D'Amico AV; Catalona WJ; Roehl KA; Kuntz KM
    Cancer; 2006 Apr; 106(7):1507-13. PubMed ID: 16518812
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Interpreting results of prostate-specific antigen testing for early detection of prostate cancer.
    Meigs JB; Barry MJ; Oesterling JE; Jacobsen SJ
    J Gen Intern Med; 1996 Sep; 11(9):505-12. PubMed ID: 8905498
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [The relationship between serum PSA value and the weight of the inner gland of the prostate in the cases of benign prostatic hyperplasia].
    Wu B; Itoh Y; Saitoh M; Watanabe H
    Nihon Hinyokika Gakkai Zasshi; 1995 Oct; 86(10):1525-9. PubMed ID: 7474601
    [TBL] [Abstract][Full Text] [Related]  

  • 74. PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases.
    Aksoy Y; Oral A; Aksoy H; Demirel A; Akcay F
    Ann Clin Lab Sci; 2003; 33(3):320-3. PubMed ID: 12956448
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Importance of specific prostatic antigen to prostatic volume ratio in the selection of patients for ultrasonography-guided biopsy of the prostate].
    Veneziano S; Pavlica P; Querzè R; Viglietta G; Trenta A
    Radiol Med; 1991 Jun; 81(6):857-60. PubMed ID: 1713333
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Free-to-total prostate-specific antigen (PSA) ratio improves the specificity for detecting prostate cancer in patients with prostatism and intermediate PSA levels.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Goepel M; Tscholl R
    Br J Urol; 1998 Apr; 81(4):532-8. PubMed ID: 9598623
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
    Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
    Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Age and total and free prostate-specific antigen levels for predicting prostate volume in patients with benign prostatic hyperplasia.
    Coban S; Doluoglu OG; Keles I; Demirci H; Turkoglu AR; Guzelsoy M; Karalar M; Demirbas M
    Aging Male; 2016 Jun; 19(2):124-7. PubMed ID: 26872869
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Influence of prostatic disease and prostatic manipulations on the concentration of prostate-specific antigen.
    Walz PH; Schoppmann T; Büscher C; Ennen J; Schriewer H
    Eur Urol; 1992; 22(1):20-6. PubMed ID: 1385141
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
    Morlock R; Goodwin B; Gomez Rey G; Eaddy M
    Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.